skip to main content
Close Icon We use cookies to improve your website experience.  To learn about our use of cookies and how you can manage your cookie settings, please see our Cookie Policy.  By continuing to use the website, you consent to our use of cookies.
Global Search Configuration
  • Close Icon

Abbott_building

 

Abbott Laboratories Inc.is launching a new portable point-of-care test that can detect COVID-19 within five minutes, the company announced on March 27.

The new test, ID NOW COVID19, will run on Abbott’s portable POC platform ID NOW and deliver positive results in as little as five minutes, the company says. Negative results are delivered in thirteen minutes.

The test has been issued an emergency use authorization (EUA) by the US Food and Drug Administration and is expected to be available in the US this week.

As the pandemic unfolds, there have been repeated calls to increase availability of rapid testing. POC tests such as Abbott’s ID NOW may play an important role in diagnosing infection, but the sensitivity and specificity of these rapidly developed tests are also being questioned.

It is the second COVID-19 test to receive an EUA. Last week Abbott launched the Abbott m2000 RealTime SARS-CoV-2 test. Between the two platforms, Abbott said it expects to produce about 5 million tests per month.  (Also see "Abbott Receives Emergency Use Authorization For COVID-19 Test" - Medtech Insight, 19 Mar, 2020.)

[Editor’s note:Medtech Insight is tracking the global diagnostic pipeline of COVID-19 tests. See ourCOVID-19 test trackerfor a full listing.]

おすすめのニュース&レポート

;

お問い合わせ&レポートストア

専任スタッフによるデモンストレーションを兼ねたサービスの詳しいご説明、または無料トライアルを常時受け付けています。ご希望の場合は下記のフォームよりお気軽にお申し込みください。

*一部のサービスでは無料トライアルをご利用になれません。

ご質問等ございましたらお気軽にご連絡下さい。

日本(平日:9時~18時)
電話:+81 (0)3 6273 4260
Email:inquiry.jp@informa.com

オンラインショップのレポートストアでは、医療用医薬品の市場調査・分析レポートを常時1000本以上販売しています。レポート1本単位で購入でき、オンラインでご提供いたします。

お探しの情報が見つからない場合はお問い合わせ先までお気軽にご連絡ください。